SIRT2 inhibition reverses anhedonia in the VGLUT1+/− depression model

Behavioural Brain Research

Volumn 335, Issue , 2017, Pages 128-131

  Munoz Cobo I ^a   Belloch, F B ^a   Diaz Perdigon T ^a   Puerta, E ^a   Tordera, R M ^a  

^a UNIVERSITY OF NAVARRA   (Spain)

Author keywords

33i; Anhedonia; Histone acetylation; Imipramine; Major depression; Prefrontal cortex (PFC); Sirtuin 2 (SIRT2)

Indexed keywords

2 [3 (3 FLUOROPHENETHYLOXY)PHENYLAMINO]BENZAMIDE; AMINE OXIDASE (FLAVIN CONTAINING); BENZAMIDE; HISTONE DEACETYLASE; IMIPRAMINE; MESSENGER RNA; NORADRENALIN TRANSPORTER; SEROTONIN TRANSPORTER; SIRTUIN 2; UNCLASSIFIED DRUG; VESICULAR GLUTAMATE TRANSPORTER 1; ANTIDEPRESSANT AGENT; GLUTAMIC ACID; SEROTONIN; SIRT2 PROTEIN, MOUSE; SLC17A7 PROTEIN, MOUSE;

ANHEDONIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD GLUCOSE MONITORING; C57BL 6 MOUSE; CONTROLLED STUDY; DEPRESSION; DISEASE MODEL; DRUG EFFECT; ENZYME ACTIVITY; ENZYME INHIBITION; GENE EXPRESSION; GENETIC REGULATION; GENOTYPE; HISTONE ACETYLATION; IN VITRO STUDY; MALE; MOUSE; NONHUMAN; PREFRONTAL CORTEX; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; REAL TIME POLYMERASE CHAIN REACTION; SUGAR INTAKE; WILD TYPE MOUSE; ANIMAL; ANTAGONISTS AND INHIBITORS; C57BL MOUSE; GENETICS; MENTAL STRESS; METABOLISM; PHYSIOLOGY;

ANHEDONIA; ANIMALS; ANTIDEPRESSIVE AGENTS; DEPRESSION; DISEASE MODELS, ANIMAL; GLUTAMIC ACID; HISTONE DEACETYLASES; IMIPRAMINE; MALE; MICE; MICE, INBRED C57BL; PREFRONTAL CORTEX; RNA, MESSENGER; SEROTONIN; SIRTUIN 2; STRESS, PSYCHOLOGICAL; VESICULAR GLUTAMATE TRANSPORT PROTEIN 1;

EID: 85027552787     PISSN: 01664328     EISSN: 18727549     Source Type: Journal    
DOI: 10.1016/j.bbr.2017.07.045     Document Type: Article

References (25)

1. Belzeaux, R., Formisano-Tréziny, C., Loundou, A., Boyer, L., Gabert, J., Samuelian, J.-C., et al. Clinical variations modulate patterns of gene expression and define blood biomarkers in major depression. J. Psychiatr. Res. 44 (2010), 1205–1213.
2. Covington, H.E., Maze, I., Vialou, V., Nestler, E.J., Antidepressant action of HDAC inhibition in the prefrontal cortex. Neuroscience 298 (2015), 329–335.
3. Elizalde, N., Gil-Bea, F.J., Ramírez, M.J., Aisa, B., Lasheras, B., Rio, J., Del, et al. Long-lasting behavioral effects and recognition memory deficit induced by chronic mild stress in mice: effect of antidepressant treatment. Psychopharmacology (Berl.) 199 (2008), 1–14.
4. Erburu, M., Muñoz-Cobo, I., Diaz-Perdigon, T., Mellini, P., Suzuki, T., Puerta, E., et al. SIRT2 inhibition modulate glutamate and serotonin systems in the prefrontal cortex and induces antidepressant-like action. Neuropharmacology 117 (2017), 195–208.
5. Erburu, M., Muñoz-Cobo, I., Domínguez-Andrés, J., Beltran, E., Suzuki, T., Mai, A., et al. Chronic stress and antidepressant induced changes in Hdac5 and Sirt2 affect synaptic plasticity. Eur. Neuropsychopharmacol. 25 (2015), 2036–2048.
6. Eskandarian, H.A., Impens, F., Nahori, M.-A., Soubigou, G., Coppée, J.-Y., Cossart, P., et al. A role for SIRT2-dependent histone H3K18 deacetylation in bacterial infection. Science, 341, 2013, 1238858.
7. Garcia-Garcia, A.L., Elizalde, N., Matrov, D., Harro, J., Wojcik, S.M., Venzala, E., et al. Increased vulnerability to depressive-like behavior of mice with decreased expression of VGLUT1. Biol. Psychiatry 66 (2009), 275–282.
8. Hobara, T., Uchida, S., Otsuki, K., Matsubara, T., Funato, H., Matsuo, K., et al. Altered gene expression of histone deacetylases in mood disorder patients. J. Psychiatr. Res. 44 (2010), 263–270.
9. Keedwell, P.A., Andrew, C., Williams, S.C.R., Brammer, M.J., Phillips, M.L., The neural correlates of anhedonia in major depressive disorder. Biol. Psychiatry 58 (2005), 843–853.
10. Lally, N., Nugent, A.C., Luckenbaugh, D.A., Niciu, M.J., Roiser, J.P., Zarate, C.A., Neural correlates of change in major depressive disorder anhedonia following open-label ketamine. J. Psychopharmacol. 29 (2015), 596––607.
11. Machado-Vieira, R., Ibrahim, L., Zarate, C.A. Jr., Histone deacetylases and mood disorders: epigenetic programming in gene-environment interactions. CNS Neurosci. Ther. 17 (2011), 699–704.
12. Marcusson, J., Eriksson, K., Dissociation kinetics of [3H]paroxetine binding to rat brain consistent with a single-site model of the antidepressant binding/5-hydroxytryptamine uptake site. J. Neurochem. 51 (1988), 1477––81.
13. Ookubo, M., Kanai, H., Aoki, H., Yamada, N., Antidepressants and mood stabilizers effects on histone deacetylase expression in C57BL/6 mice: brain region specific changes. J. Psychiatr. Res. 47 (2013), 1204–1214.
14. Renthal, W., Maze, I., Krishnan, V., Covington, H.E., Xiao, G., Kumar, A., et al. Histone deacetylase 5 epigenetically controls behavioral adaptations to chronic emotional stimuli. Neuron 56 (2007), 517–529.
15. Sarkar, A., Chachra, P., Kennedy, P., Pena, C.J., Desouza, L.A., Nestler, E.J., et al. Hippocampal HDAC4 contributes to postnatal fluoxetine-evoked depression-like behavior. Neuropsychopharmacology 39 (2014), 2221–2232.
16. Schroeder, F.A., Lewis, M.C., Fass, D.M., Wagner, F.F., Zhang, Y.-L., Hennig, K.M., et al. A selective HDAC 1/2 inhibitor modulates chromatin and gene expression in brain and alters mouse behavior in two mood-related tests. PLoS One, 8, 2013, e71323.
17. Stasiuk, W., Szopa, A., Serefko, A., Wyska, E., Świąder, K., Dudka, J., et al. Influence of the selective antagonist of the NR2 B subunit of the NMDA receptor, traxoprodil, on the antidepressant-like activity of desipramine, paroxetine, milnacipran, and bupropion in mice. J. Neural Transm. 124 (2017), 387––396.
18. Suzuki, T., Khan, M.N.A., Sawada, H., Imai, E., Itoh, Y., Yamatsuta, K., et al. Design, synthesis, and biological activity of a novel series of human sirtuin-2-selective inhibitors. J. Med. Chem. 55 (2012), 5760––5773.
19. Tong, J., Hornykiewicz, O., Kish, S.J., Identification of a noradrenaline-rich subdivision of the human nucleus accumbens. J. Neurochem. 96 (2006), 349–354.
20. Tordera, R.M., Monge, A., Río, J., Del Lasheras, B., Antidepressant-like activity of VN2222: a serotonin reuptake inhibitor with high affinity at 5-HT1A receptors. Eur. J. Pharmacol. 442 (2002), 63–71.
21. Tordera, R.M., Totterdell, S., Wojcik, S.M., Brose, N., Elizalde, N., Lasheras, B., et al. Enhanced anxiety, depressive-like behaviour and impaired recognition memory in mice with reduced expression of the vesicular glutamate transporter1 (VGLUT1). Eur. J. Neurosci. 25 (2007), 281–290.
22. Tsankova, N.M., Berton, O., Renthal, W., Kumar, A., Neve, R.L., Nestler, E.J., Sustained hippocampal chromatin regulation in a mouse model of depression and antidepressant action. Nat. Neurosci. 9 (2006), 519––525.
23. Watanabe, S., Iga, J., Ishii, K., Numata, S., Shimodera, S., Fujita, H., et al. Biological tests for major depressive disorder that involve leukocyte gene expression assays. J. Psychiatr. Res. 66–67 (2015), 1––6.
24. Willner, P., Chronic mild stress (CMS) revisited: consistency and behavioural-neurobiological concordance in the effects of CMS. Neuropsychobiology 52 (2005), 90–110.
25. Wojcik, S.M., Rhee, J.S., Herzog, E., Sigler, A., Jahn, R., Takamori, S., et al. An essential role for vesicular glutamate transporter 1 (VGLUT1) in postnatal development and control of quantal size. Proc. Natl. Acad. Sci. 101 (2004), 7158–7163.